Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

Cited by (999)

Items 801–900 of 999

1. (Poly)peptide-based therapy for diabetes mellitus: Insulins versus incretins
   Aljoša Bavec · 2014 · Life Sciences
2. Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches
   J.B. Møller, Niels Rode Kristensen, Søren Klim, MO Karlsson, SH Ingwersen, MC Kjellsson · 2014 · CPT Pharmacometrics & Systems Pharmacology
3. Managing Diabetes From First Diagnosis
   Davida F. Kruger · 2012 · The Science of Diabetes Self-Management and Care
4. Can Therapies That Target the Incretin System Improve Our Ability to Treat Type 2 Diabetes?
   Thaddeus John Bell, Eugene E. Wright · 2010 · Journal of the National Medical Association
5. Insulin tolerance test predicts non response vs. sustained efficacy of Liraglutide on glycemic control in type 2 diabetes patients: A prospective real-world setting study
   Natacha Germain, Y. Khalfallah, Bruno Estour, Bogdan Galusca · 2017 · Diabetes Research and Clinical Practice
6. Synergistic insulinotropic effect of metformin-Mg2+ adjunct supplement: A case study of streptozotocin-induced type 2 diabetes in sprague dawley rats
   Oluwaseun Fapohunda · 2018 · Journal of Diabetes Metabolic Disorders & Control
7. An Exceedingly Rare Case of Liraglutide-Induced Liver Injury
   Swetha Parvataneni, Rajarajeshwari Ramachandran, Eric O. Then, Tyler Grantham, Vinaya V. Gaduputi · 2021 · Case Reports in Gastrointestinal Medicine
8. The role of Recent Pharmacotherapeutic Options on the Management of Treatment Resistant Type 2 Diabetes
   Jeffrey M. Kroopnick, Stephen N. Davis · 2022 · Expert Opinion on Pharmacotherapy
9. Uncertainties around incretin-based therapies: A literature review
   Bader Al Tulaihi, Samia M. Alhabib · 2015 · Saudi Pharmaceutical Journal
10. Efficacy and tolerability of GLP-1 agonists in patients with type 2 diabetes mellitus: an Indian perspective
    Mala Dharmalingam · 2014 · Therapeutic Advances in Endocrinology and Metabolism
11. Glycemic Control Impact on Body Weight Potential to Reduce Cardiovascular Risk
    Giorgio Sesti · 2011 · Diabetes Care
12. Glucagon like peptide-1 receptor agonist (GLP-1RA) therapy in management of type 2 diabetes: choosing the right agent for individualised care
    Zin Zin Htike, Francesco Zaccardi, Sudesna Chatterjee, Kamlesh Khunti, Melanie Jane Davies · 2016 · British Journal of Diabetes
13. Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study
    Alessandro Ciresi, Enrica Vigneri, Stefano Radellini, Felicia Pantò, Carla Santos de Souza Giordano · 2017 · Diabetes Therapy
14. Counselling patients for GLP-1 analogue therapy: Comparing GLP-1 analogue with insulin counselling
    Bharti Kalra, Sanjay Kalra · 2012 · North American Journal of Medical Sciences
15. The non-glycemic effects of incretin therapies on cardiovascular outcomes, cognitive function and bone health
    Amir Hanna, Kim Alexander Connelly, Robert G. Josse, Roger S. McIntyre · 2014 · Expert Review of Endocrinology & Metabolism
16. Safety and efficacy of the combination of the glucagon‐like peptide‐1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: <i>Post‐hoc</i> analysis of a randomized, 52‐week, open‐label, parallel‐group trial
    Kiyosue, Arihiro, Seino, Yutaka, Nishijima, Keiji, Bosch‐Traberg, Heidrun, Kaku, Kohei · 2018 · Journal of Diabetes Investigation
17. Simplification of Complex Insulin Regimens with IdegLira in People with Type 2 Diabetes: Literature Review and Clinical Recommendations
    Carlos Esteban Builes-Montaño, Edwin Antonio Wandurraga-Sánchez, Álex Ramírez, J. E. Ordóñez · 2023 · Diabetes Therapy
18. Label-free quantitative proteomic profiling reveals differential plasma protein expression in patients with obesity after treatment with liraglutide
    Afshan Masood, Hicham Benabdelkamel, Salini Scaria Joy, Abdulaziz Alhossan, Bashayr M. Alsuwayni, Ghalia N. Abdeen, Madhawi Aldhwayan, Nora A. Alfadda, Alexander Dimitri Miras, Assim Abdulaziz Alfadda · 2024 · Frontiers in Molecular Biosciences
19. Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.
    Craig Spellman · 2012 · PubMed
20. Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor Agonists
    ROBERT J. CHILTON · 2015 · Journal of Diabetes & Metabolism
21. Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives
    Wuquan Deng, Sheng Qiu, Gangyi Yang, Bing Chen · 2015 · Therapeutics and Clinical Risk Management
22. Is treatment with liraglutide efficient?
    Pedro Mezquita Raya, Rebeca Reyes‐García · 2014 · Endocrinología y Nutrición (English Edition)
23. Pharmacotherapy for obesity: a field in crisis?
    Wiebke Kristin Fenske, Jennifer Parker, Stephen Robert Bloom · 2011 · Expert Review of Endocrinology & Metabolism
24. Review: The evolving world of GLP-1 agonist therapies for type 2 diabetes
    Kevin Baynes · 2010 · Therapeutic Advances in Endocrinology and Metabolism
25. The seven-year rule for safer prescribing
    Sidney M. Wolfe · 2012 · Australian Prescriber
26. Network meta-analysis accurately predicted the outcome of a subsequent randomised trial comparing once weekly dulaglutide 1.5 mg and once daily liraglutide 1.8 mg
    Jessie L. Fahrbach, Haoda Fu, Linda Shurzinske, Zachary Skrivanek, Sherry Martin · 2016 · International Journal of Clinical Practice
27. Effectiveness, Safety, and Patient Satisfaction of Liraglutide in Type 2 Diabetic Patients
    Rafia Zameer, Matiullah Kamin, Umar Yousuf Raja, Muhammad Umar Wahab, Osama Ishtiaq, Kashif Raashid, Naveed Ahmed, Asim ur Rehman · 2020 · Cureus
28. Diabetes-Related Effectiveness and Cost of Liraglutide or Insulin in German Patients with Type 2 Diabetes: A 5-Year Retrospective Claims Analysis
    Thomas Wilke, S. Mueller, Andreas Fuchs, Margit S. Kaltoft, Stefan Kipper, Małgorzata Cel · 2020 · Diabetes Therapy
29. An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method
    Alan Martin, Daniel C. Parks · 2016 · Diabetes Metabolic Syndrome and Obesity
30. Observational and clinical trial findings on the comparative effectiveness of diabetes drugs showed agreement
    James Flory, Alvin I. Mushlin · 2014 · Journal of Clinical Epidemiology
31. Bioequivalence Comparison of Two Formulations of Fixed-Dose Combination Glimepiride/Metformin (2/500 mg)Tablets in Healthy Volunteers.
    Sang-Hoon Jung, Jung‐woo Chae, Byungjeong Song, Kwang-Il Kwona · 2014 · PubMed Central
32. Current developments in the treatment of diabetes: the incretin therapies
    David L Russell-Jones · 2010 · The British Journal of Diabetes
33. Clinical Pearls for Initiating and Utilizing Liraglutide in Patients With Type 2 Diabetes
    Ben Gross · 2012 · Journal of Pharmacy Practice
34. The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis
    Bing-Syuan Zeng, Jiann-Jy Chen, Chih-Wei Hsu, Chao-Ming Hung, Bing‐Yan Zeng, Mein‐Woei Suen, Wei-Chieh Yang, Hung-Yu Wang, Yow-Ling Shiue, Kuan-Pin Su et al. · 2026 · Clinical Microbiology and Infection
35. Agonistas de GLP-1 en el control glucémico y ponderal de la diabetes tipo 2. Nuevas perspectivas
    Silvia Patricia Alonso, Sergio Valdés, Viyey Kishore Doulatram‐Gamgaram · 2025 · Medicina Clínica (English Edition)
36. Once‐daily liraglutide (1.2 mg) compared with twice‐daily exenatide (10 μg) in the treatment of type 2 diabetes patients: An indirect treatment comparison meta‐analysis
    Stephen Morris Twigg, Mirella M. Daja, Beth O’Leary, MICHAEL A. ADENA · 2016 · Journal of Diabetes
37. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates
    Agata Schubert, Anders T. Buchholt, Antoine C. El Khoury, Ahmed Kamal, V. Taieb · 2017 · Current Medical Research and Opinion
38. The Multicenter, Open-Label, Observational LEAD-Ph Study: Real-World Safety and Effectiveness of Liraglutide in Filipino Participants with Type 2 Diabetes
    Cecilia Jimeno, Sjoberg Kho, Grace Ko de los Santos, Neslie Buena-Bobis, Michael Lim Villa · 2018 · Journal of the ASEAN Federation of Endocrine Societies
39. Design and synthesis of rhamnose-modified exenatide conjugate by sortase A-mediated ligation
    Chen Li, Shijie Dai, Aijie Cao, Zhifang Zhou, Zhimeng Wu · 2019 · Journal of Carbohydrate Chemistry
40. Pathophysiologic Approach to Type 2 Diabetes Management: One Centre Experience 1980–2020
    Rudolf Chlup, Richard Kaňa, Lada Hanáčková, Hana Zálešáková, Blanka Doubravová · 2021 · IntechOpen eBooks
41. To Assess Liraglutide’s Therapeutic Effect in Patients with Type 2 Diabetes Mellitus Using Flash Glucose Monitoring System
    Jianhong Yin, Minmin Han, Linhui Li, Yang Li, Ziang Liu, Jing Yang, Yunfeng Liu · 2021 · Diabetes Metabolic Syndrome and Obesity
42. Safety and Efficacy of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
    Hema Srikanth Vemulapalli, Jaahnavi Vajje, Wajeeh Ur Rehman, Ghazala S. Virk, Krushi Shah, Sandipkumar S Chaudhari, IRFAN-UD-DIN MIAN, Faraz Saleem · 2023 · Cureus
43. Neue Arzneimittel 2009
    Uwe Fricke, U. Schwabe · 2010 · Springer eBooks
44. FARMACOLOGIA DO DIABETES MELLITUS TIPO 2: ANTIDIABÉTICOS ORAIS, INSULINA E INOVAÇÕES TERAPÊUTICAS
    Vannessa Passos Lopes, Manoelito Coelho dos Santos, Aníbal de Freitas Santos Júnior, Amália Ivine Costa Santana · 2012 · Revista Eletrônica de Farmácia
45. Liraglutide increases 24-h heart rate by reducing the cardiac parasympathetic activity of patients with type 2 diabetes: power spectral analysis of heart rate variability on 24-h Holter ECG recordings
    Kenji Hara, Yoshimasa Aso, Takaaki Komatsu, Takafumi Nakamachi, Yoshihiko Sakai, Kan Takayanagi, Kikuo Kasai, Toshihiko Inukai · 2014 · Diabetology International
46. Liraglutide in Combination with Metformin or Sulfonylurea for the Treatment of Type 2 Diabetes in Adult patients
    Maneesh Udiawar, Stephen Charles Bain · 2012 · Clinical Medicine Insights Therapeutics
47. ¿Es eficiente el tratamiento con liraglutida?
    Pedro Mezquita Raya, Rebeca Reyes‐García · 2013 · Endocrinología y Nutrición
48. Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?
    Richard Simpson, Allen Bennett King · 2015 · Expert Review of Clinical Pharmacology
49. Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies
    Paul M. Stranges, Ujjaini Khanderia · 2012 · Therapeutic Advances in Drug Safety
50. Non-Insulin Treatments for Diabetes
    Eugenio Angueira-Serrano · 2013 · American Journal of Therapeutics
51. Enhancing the Activity of Peroxisome Proliferator- Activated Receptor’s (PPAR) Activity through Natural Ligand Binding in Diabetes: Substantial Computational Approach
    Lakshmi Huttada, Murigendra Basayya Hiremath · 2016
52. The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial
    Silvia Lapertosa, Gustavo Daniel Frechtel, Elise Hardy, Leobardo Sauque‐Reyna · 2016 · Diabetes Research and Clinical Practice
53. Managing Cardiovascular Complications in Diabetes
    John D. Betteridge, Stephen James Nicholls · 2014 · Wiley eBooks
54. Therapeutic choices, and the nurse practitioner's role, in type 2 diabetes when metformin alone is no longer enough
    Kathryn Tierney · 2012 · Journal of the American Academy of Nurse Practitioners
55. Retracted : Salidroside from Rhodiola wallichiana var. cholaensis reverses insulin resistance and stimulates the GLP‐1 secretion by alleviating ROS‐mediated activation of MAPKs signaling pathway and mitigating apoptosis
    Tingxu Yan, Tingting Nian, Fuyuan Li, Bosai He, Ying Jia, Kaishun Bi, Zhenzhong Wang · 2020 · Journal of Food Biochemistry · Retracted
56. Liraglutida en el tratamiento de la diabetes tipo 2:
    Francisco Javier Ampudia‐Blasco, Carlos Calvo Gómez, Xavier Cos, Javier García Alegría, Esteban Jódar Gimeno, José Javier Mediavilla Bravo, Pedro Mezquita Raya, Jorge Navarro Pérez, Manel Puig‐Domingo · 2010 · Avances en Diabetología
57. The Influence of Incretin Mimetics on Cardiovascular Risk Factors in Diabetes
    I Kinalska, Dorota Bednarska-Chabowska, Joanna Adamiec-Mroczek, Łukasz Hak · 2012 · ISRN Endocrinology
58. Incretin therapy for type 2 diabetes mellitus
    D. Klonoff · 2010 · Advances in Therapy
59. Impact of glucagon‐like peptide‐1 (7‐36) amide, isosteviol and 5‐aminoimidazole‐4‐carboxamide 1‐ β ‐ d ‐ribofuranoside on leucine‐mediated α ‐cell dysfunction
    X. Chen, Kjeld Hermansen, Palle Bekker Jeppesen · 2012 · Diabetes Obesity and Metabolism
60. Next-Generation GLP-1 Therapy: An Introduction to Liraglutide
    Thomas B. Repas · 2011 · Postgraduate Medicine
61. Dapagliflozin combination therapy in type 2 diabetes mellitus
    Tamer G. Yacoub · 2015 · Postgraduate Medicine
62. Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists
    Awadhesh Kumar Singh, Ritu Singh · 2017 · Expert Review of Clinical Pharmacology
63. Effect of Glucagon-like peptide-1 agonist (liriglutide) on weight and glycemic control among adults with type 2 diabetes mellitus attending primary care center at security forces hospital in Riyadh, Saudi Arabia
    NaifahK Alanazi, MedhatA Ghoraba · 2020 · Journal of Family Medicine and Primary Care
64. Glucagon-Like Peptide-1 and Diabetes 2012
    Matteo Monami, Giovanni Di Pasquale, Anne M. Rowzee, Carlo Maria Rotella, Edoardo Mannucci · 2012 · Experimental Diabetes Research
65. Incretin‐based therapies
    Michael Albrecht Nauck, Juris Jendrik Meier · 2015
66. Investigating the potential non‐authorized use of two different formulations of liraglutide in Europe: A real‐world drug utilization study
    Sbraccia, Paolo, Aberle, Jens, Olsen, Anne Helene, Rathor, Naveen, Major‐Pedersen, Atheline · 2023 · Diabetes, Obesity and Metabolism
67. Exposure–Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Treated with Metformin
    Qinghua Wang, Fan Jiang, Yulong Xu, Yuyang Lei, Li Zhang, Xiaodong Sun · 2025 · Clinical Pharmacokinetics
68. The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome
    Sonal Rajesh Kumar, John E. Anderson, Andrea D. Coviello, F. Lopez-Jimenez, George L. Bakris · 2026 · JACC Advances
69. GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease
    Ayush Gandhi, Ei Moe Phyu, Kwame Koom‐Dadzie, Kodwo Bosomefi Dickson, Josiah K. Halm · 2026 · International Journal of Molecular Sciences
70. Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes
    Caterina Conte, Anastassia Amaro · 2026 · Current Diabetes Reports
71. Racial and demographic disparities in glp-1ra use among breast cancer patients with Type 2 Diabetes
    Jasmin Hundal, Omer Sayed Ashruf, Hong Li, Karen Basen‐Engquist, David C. Kaelber, Jasmine Singh Sukumar · 2025 · npj Breast Cancer
72. Effectiveness of Liraglutide in Type II Diabetes Mellitus Management: Experience in Emirati Patients
    Nasrullah K. Ghuman, Loai M. Saadah, Majdi AlNajjar, Duha Y. Shaheen, Ibrahim Ben Shady, Mouza M. Al Ali · 2015 · Clinical Medicine Insights Endocrinology and Diabetes
73. Type 2 diabetes: which drug as add-on to metformin?
    Sten Madsbad · 2012 · The Lancet
74. Liraglutide withdrawal rates: ‘real world’ practice
    Anjali Balasanthiran, Neil M. Munro, Kenneth Watters, Alan J Poots, Daniel L. Morganstein, MD Feher · 2012 · Practical Diabetes
75. Liraglutide With or Without Metformin Ameliorates Liver Function and Fatty Liver in Obese Patients with Type 2 Diabetes Mellitus
    Tadashi Iwao Kenji Sakai · 2015 · Journal of Diabetes & Metabolism
76. WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
    Julie A. Lovshin · 2017 · Canadian Journal of Diabetes · Retracted
77. Beginning With Very Low Dose (0.2mg) Liraglutide in Indian Type 2 Diabetic Patients Appears Better Tolerated: Experience from Real Life Practice
    Anirban Majumder · 2017 · Journal of Diabetes Metabolic Disorders & Control
78. Predictors of efficacy of Sodium‐GLucose Transporter‐2 inhibitors and Glucagon‐Like Peptide 1 receptor agonists: A retrospective cohort study
    Daniele Scoccimarro, Giacomo Cipani, Ilaria Dicembrini, Edoardo Mannucci · 2023 · Diabetes/Metabolism Research and Reviews
79. Towards Optimal Cardiovascular Health: A Comprehensive Review of Preventive Strategies
    Philip Branigan, Y. V Duong, Ammar Abdulfattah, Jacob Sabu, Mary C. Mallappallil, Sabu John · 2024 · Cureus
80. Cardiovascular safety of liraglutide for the treatment of type 2 diabetes
    RA Chudleigh, Steve Bain · 2017 · Expert Opinion on Drug Safety
81. Diabetes management: Beyond hemoglobin A1c
    Vinni Makin, Maria Cecilia Lansang · 2019 · Cleveland Clinic Journal of Medicine
82. A review on the current drugs and new targets for obesity
    M J Poojashree · 2020 · Journal of Applied Pharmaceutical Research
83. Effects of Metformin &/or Glimepiride on Resistin Level and Related Biochemical Markers in Type 2 Diabetes Mellitus
    Hadeel Delman Najim, Ibrahim Adham Majeed, Abbas Mahdi Rahmah · 2014 · Al Mustansiriyah Journal of Pharmaceutical Sciences
84. Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults
    Mohamad Sirri Tarazi, Samir Touhamy, Beverly G. Tchang, Alpana P. Shukla · 2021 · Expert Opinion on Pharmacotherapy
85. Liraglutide for the treatment of type 2 diabetes : a single technology appraisal
    D Shyangdan, Eleanor Cummins, Pamela Royle, Norman R Waugh · 2011 · Warwick Research Archive Portal (University of Warwick)
86. Clinical experience with liraglutide
    Stephen Charles Bain, J. McKenna · 2010 · International Journal of Clinical Practice
87. Treatment options for type 2 diabetes:introducing the incretin‐based therapies
    A H Barnett · 2009 · Practical Diabetes
88. Is Liraglutide A Useful Addition to Diabetes Therapy?
    Nasser E. Mikhail · 2010 · Endocrine Practice
89. Management of Unmet Needs in Type 2 Diabetes Mellitus: The Role of Incretin Agents
    Ronald Goldenberg · 2011 · Canadian Journal of Diabetes
90. What proportion of patients fail NICE criteria for continuing GLP‐1 treatment beyond six months, and why?
    L Wessels, Suzanne Keigan, SV O'Brien, KJ Hardy · 2013 · Practical Diabetes
91. Insulin und Diabetes mellitus Typ 2
    A Lanker, Bruno Müller, Peter Diem · 2009 · Therapeutische Umschau
92. Incretin-based Therapies (Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors) for the Treatment of Type 2 Diabetes
    Amir Hanna, Vincent C. Woo, Jean‐François Yale, Elaine M. Cooke · 2012 · Canadian Journal of Diabetes
93. Liraglutide, the once-daily human GLP-1 analog, in the treatment of Type 2 diabetes
    Marta Letizia Hribal, Giorgio Sesti · 2010 · Expert Review of Endocrinology & Metabolism
94. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide
    Louise Vedtofte, Filip Krag Knop, Tina Vilsbøll · 2015 · Expert Review of Clinical Pharmacology
95. ¿Existe un espacio para los análogos de la incretina como terapia para el sobrepeso, la obesidad y la prevención de la enfermedad cardio-metabólica?
    José López-López, Karina A. Di Stefano, Elizabeth Velásquez, Paul Anthony Camacho, Patricio A López-Jaramillo · 2015 · Revista Colombiana de Cardiología
96. Liraglutide in clinical practice: Glycemic control, and predictors of good response
    Albert Lecube, Cyntia Gonzalez, Cristóbal Morales · 2015 · Medicina Clínica
97. Traitement du diabète en dehors de l'insuline
    Jean‐Frédéric Blickle · 2011 · EMC - Endocrinologie - Nutrition
98. Lipid Lowering Effect of Anti Diabetic Agents-Recent Research
    N. Pavithra, MVNL Chaitanya · 2015 · International journal of pharma research and review
99. Repurposing drugs for the treatment of glioma
    Yaodong Zhao, Chengming Xu, Congyan Wu, Lei Li · 2019 · Glioma
100. Effects of Incretin-based Therapies on Weight-related Indicators among Patients with Type 2 Diabetes: A Network Meta-analysis.
     Lu Xu, Shu Qing Yu, Le Gao, Yi Huang, Shan Wu, Jun Yang, Yi Xin Sun, Zhicheng Yang, San Bao Chai, Yuan Zhang et al. · 2020 · PubMed